BioInvent International AB

BioInvent International AB is a biopharmaceutical company specializing in the discovery, development, and manufacturing of therapeutic antibodies targeting diseases with significant unmet medical needs, such as cancer, HIV infection, thrombosis, atherosclerosis, and joint diseases. The company leverages its proprietary n-CoDeR antibody library and a fully integrated research engine for rapid selection, production, and validation of human antibodies in pre-clinical and early clinical trials, while partnering with pharmaceutical giants like GlaxoSmithKline and ImmunoGen for further development. Headquartered in Lund, Sweden, BioInvent operates a state-of-the-art GMP facility with 200 and 1000L single-use bioreactors, providing Contract Development and Manufacturing Organization (CDMO) services, including cell line development using a royalty-free GS knocked CHO K1 platform, process optimization, analytical support, and QP release for clinical trials. As a leader in antibody immuno-oncology, it maintains a broad clinical pipeline of first-in-class candidates and supports partners in advancing innovative biologics within the rapidly expanding pharmaceutical antibodies market. With around 92 employees, BioInvent plays a key role in bridging innovative antibody technologies from research to clinical application.